Kronox Lab Sciences IPO lists 21% premium in 2024 India

Listing day outcome: a positive start, then volatility

Kronox Lab Sciences Limited debuted on Indian stock exchanges on 10 June 2024 after its mainboard IPO closed earlier in the month. The stock listed at ₹165 per share on the BSE and ₹164.95 per share on the NSE. Against the final issue price of ₹136, the debut implied a listing gain of about 21.3% on both exchanges.

Trading on the listing day also showed intraday swings. After listing, the stock slipped to an intraday low of ₹156.8. Around 12:06 PM, it was reported to be trading at ₹160.5 per share, which was about 18% above the issue price at that point. Another report in Hindi noted that the stock ended the first day at ₹159.35, leaving IPO investors still up about 17.17% versus the issue price.

IPO details: dates, price band, and issue size

Kronox Lab Sciences’ IPO opened for subscription on 3 June 2024 and closed on 5 June 2024. The price band was set at ₹129 to ₹136 per share, with the final issue price fixed at ₹136. The face value was ₹10 per share and the lot size was 110 shares.

The total issue size was ₹130.15 crore. The shares were listed on both BSE and NSE on 10 June 2024 under the symbol KRONOX (BSE scrip: 544187).

Subscription: 117.25 times overall, led by NIIs

Demand during the book-building period was strong. As of 5 June 2024, the IPO was subscribed 117.25 times overall. Category-wise, the subscription was reported as 54.24 times for retail investors, 89.03 times for qualified institutional buyers (QIBs), and 301.92 times for non-institutional investors (NIIs).

The scale of demand was also reflected in bid data: the issue reportedly received bids for 78,54,49,390 shares against 66,99,000 shares on offer, translating to the same 117.25 times overall subscription.

Grey market premium signalled a similar debut

Ahead of listing, grey market indicators pointed to a debut near the eventual opening. A table in the provided data showed a grey market premium (GMP) of ₹28 per share against an IPO price of ₹136. That implied an estimated listing price around ₹164, or roughly 20.59% above the issue price, which was close to the actual listing levels reported on BSE and NSE.

At the same time, commentary accompanying the listing noted that the listing performance was seen as decent but not fully matching earlier expectations that had been influenced by GMP levels that reportedly declined as listing approached.

Company profile: Vadodara-based specialty chemicals maker

Incorporated in 2008, Kronox Lab Sciences Limited is based in Vadodara, India. The company manufactures high-purity specialty fine chemicals for diverse end-user industries. Product references in the data include high purity fine inorganic chemicals, phosphate, and metallic chemicals.

Financial snapshot shared with the listing coverage

The provided information also included a year-on-year growth snapshot. Revenue increased by 16.99% and profit after tax (PAT) rose by 21.94% between the financial year ending 31 March 2022 and 31 March 2023. No absolute revenue or PAT figures were provided alongside these growth rates.

What the market said on listing day

Listing-day commentary highlighted two points at once: strong investor interest, and the need for caution amid broader volatility. One analyst quote included in the provided text came from Shivani Nyati, Head of Wealth at Swastika Investmart, who said investors may hold their position with a stop-loss of ₹150, citing market volatility and a lower-than-expected premium compared with pre-listing expectations.

Separately, a trading-oriented suggestion in the source text said investors who applied mainly for listing gains could consider booking profits on listing day, or wait at least the first 15 minutes and then set a stop-loss at the day’s low.

Key numbers at a glance

Market capitalisation and post-listing stock snapshots

Market capitalisation figures cited in the provided text varied by source. One report put the market capitalisation on the BSE at around ₹612.22 crore, while another said the market valuation stood at ₹597.37 crore. A separate stock snapshot listed market cap at ₹526 crore, along with other metrics such as stock P/E 20.4, book value ₹27.3, dividend yield 0.35%, ROCE 43.8%, ROE 32.6%, and face value ₹10.

Another market snapshot in the provided text referenced prices around ₹123 on the NSE, an average traded price of 123.79, and a 1-year return of about -31.87%, along with a P/E (TTM) of 17.83 and a PB ratio of 4.54. The data also cited a 52-week high and low range that included values around ₹207.40 on the high side and ₹118.25 on the low side.

Why the listing matters for IPO investors

For IPO applicants, a listing premium of about 21% on the issue price created an immediate decision point between profit booking and holding. The same day also demonstrated that first-day gains can fluctuate, as seen in the drop from listing levels to an intraday low of ₹156.8 and the later close reported at ₹159.35.

For broader markets, the issue added another listed name in the specialty fine chemicals space. The heavy subscription levels across retail, QIB and especially NII categories showed strong primary market appetite during the offer window, even as listing-day commentary flagged wider market volatility.

Conclusion

Kronox Lab Sciences entered the market with a premium debut, listing near ₹165 versus an issue price of ₹136 after a 117.25 times subscription. The first day’s trading also showed sharp intraday movement, underlining why stop-loss levels and position sizing matter for IPO investors. Next data points for investors will come from subsequent trading sessions and any company updates following the listing.